5:19 PM
 | 
May 07, 2013
 |  BC Extra  |  Top Story

Isis planning potential $200M follow-on

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) released 1Q13 earnings late Tuesday and also said it plans to sell 9 million shares in a follow-on underwritten by Goldman Sachs; JPMorgan; Stifel Nicolaus Weisel;...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >